Written and maintained by CASRAI Editorial Board
Last updated
Note: This guide provides regulatory, methodological, and operational reference information for researchers, clinical investigators, and trial sponsors. It does not constitute individual medical advice or clinical treatment recommendations.
Short answer
Medical device clinical trials are prospective biomedical investigations designed to evaluate the safety, clinical performance, and clinical benefit of medical technologies in human participants. Unlike pharmaceutical trials that advance through Phases I–IV, medical device clinical studies follow an iterative, stage-based lifecycle (exploratory, pivotal, and postmarket) governed by 21 CFR Part 812 in the United States and ISO 14155 globally.
Definition and scope
A medical device clinical trial—formally referred to as a clinical investigation under international standards—is an empirical study involving human subjects to assess the safety and effectiveness of an investigational medical device. These investigations encompass physical instruments, diagnostic test systems, implantable hardware, software as a medical device (SaMD), and complex combination products.
The regulatory scope of device trials differs fundamentally from pharmacotherapy. Pharmaceutical clinical trials primarily evaluate the metabolic, biochemical, and systemic pharmacodynamics of a chemical compound across healthy volunteers and target populations. In contrast, medical device clinical research investigates physical, mechanical, thermal, electrical, or software mechanisms of action. Consequently, medical device trials almost never enroll healthy volunteers; they are conducted directly in patients with the target indication because device placement or surgical intervention carries inherent procedural risks.
Regulatory oversight depends on the jurisdiction and the risk profile of the device. In the United States, investigations are regulated by the FDA under 21 CFR Part 812 (investigational device exemption (IDE) regulations), distinguishing between significant risk (SR) devices that require both FDA and Institutional Review Board (IRB) approval, and non-significant risk (NSR) devices that require abbreviated IDE requirements and IRB approval. Internationally, ISO 14155 serves as the benchmark standard for Good Clinical Practice (GCP) for medical devices, aligned with ethical mandates from the Declaration of Helsinki and harmonized under the European Union Medical Device Regulation (EU MDR 2017/745).
How it works or how it is used in practice
The lifecycle of medical device clinical trials proceeds across three primary operational stages defined by FDA guidance and ISO 14155:
- Exploratory Stage (Early Feasibility and Pilot Studies): Early feasibility studies (EFS) or First-in-Human (FIH) investigations enroll small cohorts (typically 10 to 30 subjects) to capture initial safety data, evaluate human factors, and refine procedural technique. Insights from this stage inform iterative engineering modifications before locking device specifications.
- Pivotal Stage: The definitive confirmatory clinical study designed to collect statistically powered evidence of safety and effectiveness. Pivotal studies support Premarket Approval (PMA), De Novo requests, or select 510(k) submissions. Protocols establish primary safety and performance endpoints, powered sample sizes, and predefined statistical analysis plans.
- Postmarket Stage: Post-approval studies (under Section 522 of the FD&C Act in the U.S.) or Post-Market Clinical Follow-up (PMCF) under EU MDR evaluate long-term durability, rare device deficiencies, and performance across broader real-world clinical practices.
Operational execution requires strict alignment between engineering and clinical teams. Sponsoring organizations must establish rigorous design controls to achieve “design freeze” or “design lock” prior to initiating pivotal trials, preventing hardware or algorithmic changes from invalidating accumulated clinical datasets. Investigators and clinical site staff undergo device-specific procedural training to standardize deployment and account for operator learning curves.
Types or related concepts
Medical device clinical trial design requires selecting the appropriate control strategy, endpoint framework, and comparative methodology. The table below outlines the core structural differences between medical device clinical trials and pharmaceutical trials.
| Dimension | Medical Device Clinical Trials | Pharmaceutical Clinical Trials |
|---|---|---|
| Development Stages | Exploratory (FIH/feasibility), Pivotal, Postmarket surveillance | Phase I (safety/PK), Phase II (dose-finding), Phase III (confirmatory), Phase IV |
| Study Population | Target patient populations with condition; healthy volunteers rarely enrolled | Phase I frequently utilizes healthy adult volunteers before patient testing |
| Blinding & Controls | Challenging due to physical devices; uses sham controls, active comparators, or objective performance criteria (OPC) | Double-blind, identical placebo-controlled randomized trials are routine gold standard |
| Operator Influence | High dependence on physician skill, procedural technique, and learning curve | Minimal operator variance; standardized administration of chemical substance |
| Design Evolution | Iterative engineering tweaks early; requires formal design freeze before pivotal trial | Molecule formulation remains static throughout clinical evaluation |
| Primary Endpoints | Dual-tracked: technical device performance/success and clinical patient safety | Biochemical efficacy, clinical disease resolution, and systemic safety profile |
When double-blind randomized controlled trials (RCTs) are physically or ethically impractical, trialists employ specialized methodologies such as sham-procedure design to evaluate placebo effects in interventional procedures, or non-randomized concurrent controls and performance goals derived from historical registry data.
Where it matters for labs, clinics or supply decisions
Robust clinical trial data directly dictates clinical adoption, institutional procurement, and regulatory marketing authorizations:
- Regulatory Clearance and Market Authorization: High-risk Class III devices require robust pivotal trial evidence to support Premarket Approval (PMA) and 510(k) clearances. In Europe, the EU MDR has eliminated grandfathering, requiring clinical investigations or documented equivalence for high-risk and implantable technologies.
- Institutional Value Analysis and Hospital Purchasing: Hospital Value Analysis Committees (VACs) evaluate pivotal trial safety endpoints, procedure duration, infection rates, and complication frequencies before approving capital equipment or clinical consumables into institutional formularies.
- Health Economics and Reimbursement (HEOR): Payers and health technology assessment (HTA) bodies demand meaningful patient-centered endpoints, reduction in readmissions, and comparative effectiveness against current standards of care before assigning coverage codes and reimbursement rates.
- Investigator and Facility Logistics: Clinical research sites must maintain dedicated device accountability procedures, climate-controlled storage for investigational units, and protocols for tracking and returning explanted or deficient devices for engineering analysis.
Common misunderstandings
- Misunderstanding: All medical devices require prospective clinical trials. Reality: In the United States, the majority of Class II devices gain market clearance via the 510(k) pathway by demonstrating substantial equivalence to a legally marketed predicate device, often using bench testing and human factors data without new human clinical trials. Clinical trials are primarily required for Class III devices, De Novo classifications, novel technologies lacking predicates, or when bench testing cannot resolve safety questions.
- Misunderstanding: Device trials follow the standard Phase I–IV pharmaceutical pathway. Reality: Device regulatory frameworks do not use formal Phase I–IV terminology. Device investigations are organized into early exploratory feasibility studies, pivotal studies, and postmarket studies.
- Misunderstanding: Investigational devices can be modified at will during pivotal trials. Reality: While early feasibility trials permit iterative engineering refinements, pivotal clinical investigations require strict design lock. Significant design modifications during a pivotal trial can constitute a major protocol deviation, potentially invalidating trial data or requiring an IDE supplement.
- Misunderstanding: Blinding can always be achieved with mock devices. Reality: In many surgical or implantable device trials, true double-blinding is technically impossible or presents unacceptable ethical risks. Device trialists instead utilize blinded independent review committees (core laboratories) and masked outcome assessors to minimize evaluation bias.
Frequently asked questions
What is an Investigational Device Exemption (IDE)?
An Investigational Device Exemption (IDE) under FDA regulation 21 CFR Part 812 permits an investigational medical device to be shipped and used in a clinical study to collect safety and effectiveness data. Significant risk studies require formal FDA and IRB approval before enrollment begins, whereas non-significant risk studies operate under abbreviated IDE requirements with IRB oversight alone.
What is ISO 14155?
ISO 14155 is the internationally recognized Good Clinical Practice (GCP) standard for clinical investigations of medical devices in human subjects. It defines organizational responsibilities, ethical safeguards, risk management integration, protocol design (Clinical Investigation Plan), and adverse event reporting procedures for device trials worldwide.
How do device clinical trials account for the operator learning curve?
Because clinical outcomes with medical devices depend heavily on clinician technique, study protocols often incorporate standardized simulation training, proctored early cases, or run-in phases. Statistical analysis plans frequently adjust for operator experience to separate surgical learning curves from baseline device performance.
What is the difference between an early feasibility study (EFS) and a pivotal study?
An early feasibility study is a small, exploratory clinical investigation (often 10–30 patients) conducted early in device development to capture initial clinical safety and usability insights before final design freeze. A pivotal study is a definitive, statistically powered investigation designed to confirm device safety and effectiveness to support regulatory market authorization.
Sources
- U.S. Food and Drug Administration. (2013, November 7). Design Considerations for Pivotal Clinical Investigations for Medical Devices. Guidance for Industry, Clinical Investigators, and Food and Drug Administration Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-pivotal-clinical-investigations-medical-devices (Read: 2026-11-07).
- U.S. Food and Drug Administration. 21 CFR Part 812 — Investigational Device Exemptions. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812 (Read: 2026-11-07).
- International Organization for Standardization. (2020). ISO 14155:2020: Clinical investigation of medical devices for human subjects — Good clinical practice. https://www.iso.org/standard/71690.html (Read: 2026-11-07).
- European Union. (2017). Regulation (EU) 2017/745 of the European Parliament and of the Council on medical devices (EU MDR). Official Journal of the European Union, Chapter VI & Annex XV. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745 (Read: 2026-11-07).
